Experience ofPoliomyelitis in 1962 and 1963 The incidence of poliomyelitis in England and Wales during the past seven years is shown in Table 4 . Salk vaccine alone was used from 1957 to 1961 except during the Hull mass vaccine administration in 1961. Oral vaccine has replaced Salk vaccine progressively since February 1962 both in primary immunization and for reinforcing doses. Five million persons had received one or more doses of oral vaccine by June 1963, 1,900,000 doses being used for primary courses. In addition to routine immunization, oral vaccine was offered during 1963 to all children and even adults living in the immediate environment or in contact through school with every case of paralytic poliomyelitis. Even though this has doubtless swelled the number of patients whose illness has occurred after vaccine and who were probably incubating the disease when the latter was given, the principle of partial 'blanketing' of the immediate contacts appears to be sound in practice. Table 4 Poliomnyelitis: corrected notifications in England and Wales 1957-63 No ofcases notifiedper annum 1957 1958 1959 1960 1961 1962 1963 Table 4 shows that the number of cases of poliomyelitis notified and provisionally confirmed in 1963 was a record low total and only about onefifth of the number iin 1962. Yet this record figure occurred in a year when oral vaccine was introduced all over the country in relatively small numbers of persons. This method of using living vaccine actually affords a greater opportunity for spread of excreted virus to contacts than does simultaneous mass immunization. But in our particular setting and with previous experience of polio vaccine, the method has not caused any difficulty.
The experience of poliomyelitis over the last few years has brought one further lesson. In this phase of declining paralytic disease, it is becoming increasingly difficult to recover polioviruses from the faeces. Other enteroviruses are sometimes being recovered, however, and the role of these numerous agents in causing disease of the central nervous system is slowly becoming apparent. Clinical diagnoses and records of illness therefore require the best possible laboratory support. Fortunately the Public Health Laboratory Service is well equipped for this task. Recently there has been a tendency to dismiss formolin-inactivated poliomyelitis vaccines (Salk vaccine) as being of limited value, out of date and based on the wrong principle. Certainly it is true that Salk vaccine of the potency used in the past in the United Kingdom and North America was considerably less effective than oral vaccine (Sabin vaccine) both in conferring individual protection and herd immunity. Whether the principle of an inactivated poliomyelitis vaccine was wrong is another matter and I wish to defend this principle by presenting some of the evidence which suggests that potent Salk vaccines are capable of giving complete protection to the individual and of profoundly influencing herd immunity.
Individual Protection
Considering the problem of individual protection first, why did the Salk vaccine we used give only 80-90% protection after a course of three injections? The answer is that it failed to stimulate the production of useful levels of neutralizing antibody in a proportion of those who received it. When a potent vaccine is used high levels of antibody are reached after the third or booster dose and this results in a solid and long-lasting immunity against paralytic poliomyelitis. On the other hand, when a vaccine of poor potency is used, no proper secondary response is obtained after the booster dose and this means a less certain and less durable immunity. In the Salk vaccines which we used in the past the three separate components representing the three poliovirus types were not of equal potency. The Type 2 component was generally of good potency, but the Type 1 and Type 3 components were often of poor potency and because Type 1 poliovirus was much the most common cause of paralytic disease the vaccine, not unnaturally, failed to give complete protection. Not all countries were content with low potency standards. In Australia the Type 1 component (Duxbury et al. 1963 ) and in Sweden all three components were of higher potency (Olin 1961) . The protection given by these vaccine components appears to have been near 100%.
In the past few years Salk vaccines have been produced in the United States ) and in the United Kingdom (Beale & Ungar 1962) in which the amounts of the three antigenic components have been adjusted to give the required results in terms of antibody response. Thus the quantitative methods used in making nearly every other drug or vaccine we use have, at last, been employed in the manufacture of Salk vaccine.
The poliovirus antibody response of a group of infants with a mean age of 81 months to one of these new vaccines is shown in Table 1 . The vaccine was a quadruple vaccine containing pertussis, diphtheria and tetanus antigens in addition to the potent Salk-type antigens, and these antibody levels followed a primary course of three injections at monthly intervals. The antibody levels, which will rise even higher after the booster dose, are very much higher than those we used to get, particularly against the important Type 1 poliovirus, with old-style Salk vaccine. The response in younger infants is not as good. Antibody levels following the booster dose in a group of children with a mean age of 4 months at the start of immunization are shown in Table 2 . High levels of maternal antibody (Perkins et al. 1959 ) and perhaps also immunological immaturity account for this poorer response. Even so this is a highly satisfactory vaccine when used at this age. Since these tests were done the amounts of Types 2 and 3 antigens have been increased and the amount of Type 1 antigen slightly decreased. This kind of adjustment is now relatively simple. Table 3 compares these antibody levels with those found following a course of three doses of oral polio-vaccine.
Another type of combined vaccine contains diphtheria and tetanus antigens in addition to the potent Salk-type poliovirus antigens. This vaccine can be used to boost the immunity of children entering school. The antibody responses of a group of 5-and 6-year-old children to a single dose of the vaccine are shown in Table 4 ; they are most satisfactory.
These results suggest that with modern Salktype vaccines good levels of antibody can be achieved and that the often quoted 80 % or 90 % level of protection can be a thing of the past.
Herd Immunity
A marked decline in the incidence of paralytic poliomyelitis followed the introduction and widescale use of Salk vaccine both in the United Kingdom and in the United States. Salk (1959) has pointed out that this decline in the United States was considerably greater than could be accounted for simply on the basis of the indi-vidual protection afforded to vaccineesin other words there was evidence that some herd immunity had developed. It is interesting that Type 2 virus virtually disappeared (Bodian 1961) , but that Types 1 and 3 virus persisted, though mainly in poorly vaccinated areas. Could this have been related in any way to the differing potency of the three antigenic components of Salk vaccine? In this connexion it is worth noting that in Sweden, where potency levels were high for all three virus types, 'wild' polioviruses did virtually disappear.
The mechanism whereby Salk vaccine can influence the spread of 'wild' polioviruses in a community is of interest. In the infected person poliovirus multiplies in the throat and in the small intestine, but the relative importance of these two sites in the transmission of the infection is an unresolved problem. Probably both are important. It is generally believed that, in persons who have received Salk vaccine, virus growth in the throat is inhibited, and certainly this is what we have found in Belfast , but that multiplication in the small intestine is not. In a trial carried out in 1960 we compared the faecal virus excretion by a group of children who had received only two doses of ordinary Salk vaccine with the excretion by an unvaccinated control group after both had received a dose of attenuated Type 2 poliovirus. The mean frecal virus excretion of the two groups for the twenty-day period after feeding virus was virtually identical.
In 1963 we carried out a similar trial, but on this occasion the test group of children had received a full course of Salk vaccine and therefore had a higher mean antibody titre than the children in this first group -1: 7,000 as opposed to 1: 500.
The mean level of fecal virus excretion by the vaccinated group was only one-twentieth of that of the control group. The inhibition of throat virus multiplication together with this marked reduction in fecal virus excretion may well explain the herd immunity which has followed the use of Salk vaccine. The degree of individual protection obtained and the degree of herd immunity which follows wide-scale use both appeared to depend on vaccine potency.
Conclusion
Both oral vaccine and the new Salk vaccines appear to be efficient and have approximately equal capacities for protecting the individual and the herd. It would seem wise, until we know more about them, not to pin our faith too firmly upon one or the other. We may yet have something to learn about their safety.
Dr A T Roden (Ministry ofHealth, London) Surveillance of Salk Vaccination in England and Wales 1956-61 There are certain complications of immunizing procedures which can be recognized in the individual patient. For example, the child who develops generalized vaccinia after vaccination against smallpox is suffering from a form of illness which does not occur naturally, the lesions resemble those produced by the immunizing agent and, if confirmation is needed, vaccinia virus can be isolated from the lesions. Most local reactions to immunization can also be recognized in the individual, whether they occur soon after, like the sore arm of TAB vaccination, or are delayed, like the cysts which may develop after the injection of an oil-adjuvant vaccine. There are also certain well-established patterns of general reaction, some immediate or nearly so, such as anaphylactoid reactions, some delayed, like serum sickness.
But, when the complication or alleged complication of an immunizing procedure takes the form of an illness which may also occur naturally or spontaneously, it is usually impossible in the individual case to decide whether the illness is causally related to the immunizing procedure or not. In the early days of Salk vaccination the chief concern which was felt about the safety of the vaccine was that the polioviruses used in its preparation might have been imperfectly inactivated and so capable of giving rise to poliomyelitis in vaccinated persons and, although the most stringent laboratory tests were made on every batch of vaccine released, the ultimate assurance of safety lay in its effects when inoculated into man. In any individual instance of a person who was living in a community where natural poliovirus infection was occurring and who developed the disease soon after an injection of Salk vaccine it was impossible to say whether this was a coincidence or whether the vaccine was responsible for the illness. It was necessary, therefore, to proceed by accumulating instances of association of vaccination with subsequent poliomyelitis and comparing these with what could be
